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Abstract
Background: We developed a novel intranasal influenza vaccine approach that is based on the construction of replication-
deficient vaccine viruses that lack the entire NS1 gene (DNS1 virus). We previously showed that these viruses undergo
abortive replication in the respiratory tract of animals. The local release of type I interferons and other cytokines and
chemokines in the upper respiratory tract may have a ‘‘self-adjuvant effect’’, in turn increasing vaccine immunogenicity. As a
result, DNS1 viruses elicit strong B- and T- cell mediated immune responses.
Methodology/Principal Findings: We applied this technology to the development of a pandemic H5N1 vaccine candidate.
The vaccine virus was constructed by reverse genetics in Vero cells, as a 5:3 reassortant, encoding four proteins HA, NA, M1,
and M2 of the A/Vietnam/1203/04 virus while the remaining genes were derived from IVR-116. The HA cleavage site was
modified in a trypsin dependent manner, serving as the second attenuation factor in addition to the deleted NS1 gene. The
vaccine candidate was able to grow in the Vero cells that were cultivated in a serum free medium to titers exceeding 8 log10
TCID50/ml. The vaccine virus was replication deficient in interferon competent cells and did not lead to viral shedding in the
vaccinated animals. The studies performed in three animal models confirmed the safety and immunogenicity of the vaccine.
Intranasal immunization protected ferrets and mice from being infected with influenza H5 viruses of different clades. In a
primate model (Macaca mulatta), one dose of vaccine delivered intranasally was sufficient for the induction of antibodies
against homologous A/Vietnam/1203/04 and heterologous A/Indonesia/5/05 H5N1 strains.
Conclusion/Significance: Our findings show that intranasal immunization with the replication deficient H5N1 DNS1 vaccine
candidate is sufficient to induce a protective immune response against H5N1 viruses. This approach might be attractive as
an alternative to conventional influenza vaccines. Clinical evaluation of DNS1 pandemic and seasonal influenza vaccine
candidates are currently in progress.
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The increased circulation of highly pathogenic avian influenza
viruses in birds with a periodic lethal infection of humans has
lasted for more than ten years now. The number of people infected
by H5 influenza has already reached 408 in 2009. A very high
mortality rate (exceeding 50%) and the appearance of several
distinct clades of H5N1 viruses intensify the necessity for an
efficient cross-clade protective vaccine to prevent a possible
pandemic among the naı ¨ve human population.
Clinical trials that have been undertaken with conventional
inactivated vaccines that were made from H5N1 viruses indicated
that a high dose (up to 90 mg) and double immunization might be
essential for an efficient immune response in humans [1–4]. The
dose sparing as well as cross-neutralizing activity against
antigenically different H5N1 strains could be achieved by using
immunological adjuvants such as conventional aluminum or newly
developed oil-in-water emulsions (MF59, ASO3) [5–10]. Two
doses of aluminum adjuvanted H5N1 split vaccine elicited a
substantial immune response even in naı ¨ve children aged 6 months
to 9 years, although a higher dose of antigen per child (30 mg) was
used than what is used in a seasonal inactivated influenza vaccine
[11]. In contrast to subunit and split vaccines, a whole virion
inactivated vaccine (WIV) is more immunogenic because of the
immune adjuvant effect of viral genomic ssRNA [12,13]. It was
shown that H5N1 WIV that was produced in Vero cells did not
require the addition of adjuvant and induced a cross-clade
neutralizing antibody response after double immunization with a
7.5–15 mg dose [4]. Unfortunately, WIV may cause a high
incidence of adverse events, including local reactions at the site of
injection and febrile illness, particularly among children [14,15].
It is not clear whether the appearance of cross-reactive serum
antibodies induced by adjuvanted inactivated vaccines in humans
can secure the protection of people against an infection with
antigenically distinct H5N1 strains. Respiratory mucosa associated
secretory IgA antibodies as well as cytotoxic T lymphocytes (CTL)
were shown to be involved in cross-protection [16–25]. Several
attempts have been made to apply inactivated vaccines intranasally.
A combination of intranasally administered inactivated vaccine
preparations with mucosal adjuvants, such as cholera toxin B or
Escherichia coli heat-labile toxin B, could provide cross-protection in
mice [26–29]. Promising results were obtained in mice with an
influenza Virus-Like Particle (VLP) intranasal vaccine eliciting a
cross-protective immune response without the addition of an
adjuvant after two immunizations [30]. However, in people, the
intranasal administration of a virosomal seasonal vaccine with
Escherichia coli heat-labile toxin was associated with the appearance
of Bell’s palsy syndrome [31]. Therefore, the development of safe
and efficient mucosal adjuvants is an actual issue at hand [32,33].
Live attenuated vaccine, mimicking a natural infection, is
another option for creating broad protection at the mucosal
surfaces by an induction of not only systemic but also local IgA, as
well as T-cell responses [20,34,35]. Only preclinical data are
available on the immunogenicity and protective efficacy of H5N1
live vaccine candidates. It was demonstrated that two immuniza-
tions with a live attenuated influenza vaccine provide full
protection against pulmonary replication and death from a
heterologous H5N1 challenge virus in mouse and ferret models
[36,37]. Such vaccines can especially be useful for priming naı ¨ve
children [38–40]. However, vaccine virus replication as well as
wheezing syndrome in children 6 to 11 months of age raise some
safety concerns [41,42].
We developed a new type of intranasal influenza vaccine based
on the construction of replication-deficient influenza viruses
lacking the non-structural protein 1 (DNS1 virus). The NS1
protein is considered the major factor antagonizing the innate
immune response [43–45]. The intranasal administration of DNS1
mutant viruses causes the local induction of type I interferons
(IFN) in the absence of detectable virus replication [46]. This
approach combines the advantage of live attenuated vaccines to
induce secretory antibody as well as a cellular immune response
without the disadvantage of vaccine virus shedding.
In the present study, we demonstrate that intranasal immuni-
zation with an H5N1 DNS1 vaccine candidate induces an immune
response against the antigenic variants of modern H5N1 viruses in
mice, ferrets, and macaques. Moreover, the vaccine was able to
elicit protection against heterologous H5 challenge viruses.
Materials and Methods
Cells and Viruses
A Vero (WHO-certified) cell line was obtained from the
European Collection of Cell Cultures and was adapted and
further cultivated at 37uC and 5% CO2 in a serum-free Opti-pro
medium (Invitrogen) supplemented with 4 mM L-glutamine
(Invitrogen).
MDCK cells were cultivated at 37uC and 5% CO2 in DMEM
medium (Invitrogen) comprising 2% Fetal Bovine Serum (FBS,
Invitrogen) and 2 mM L-glutamine.
Human bronchial epithelial 16HBE14o
– (HBE) cells (obtained
from Dr J. Seipelt, Vienna, Austria) were grown in a minimal
essential medium (MEM; Invitrogen) supplemented with 10% FBS
and 2 mM L-glutamine. Dishes were coated with 10 mg/ml BSA
(Sigma), 30 mg/ml bovine collagen type I (Promocell), and 10 mg/
ml human fibronectin (BD Pharmingen) in Ham’s F12 medium
(HyClone).
All the recombinant viruses that were used in the present study
were obtained by reverse genetics solely on Vero cells. The vaccine
candidate inherited the HA, NA, and M genes from the H5N1
influenza virus A/Vietnam/1203/04 (A/VN/1203/04). The HA
polybasic cleavage site of the H5N1 highly pathogenic strain was
replaced by the trypsin specific cleavage site TETR/GLF [47].
The internal protein genes were derived from the IVR-116
vaccine strain distributed by the WHO. IVR-116 is a reassortant
that inherited HA and NA genes from influenza A/New
Caledonia/20/99 (H1N1), the PB1 gene from A/Texas/1/77
(H3N2), and all other genes from the A/Puerto Rico/8/34
(H1N1) (PR8) virus. Virus IVR-116 was adapted to Vero cells
resulting in the appearance of mutations in PA (N10S, P275L, and
D682N), NP (S287N), M1 (A146T), and M2 (A27T) proteins. The
NS1 open reading frame (ORF) was deleted in the NS segment, as
described in Garcia-Sastre et al. [44]. The resulting virus was
named VN1203DNS1.
Additional influenza A viruses were constructed as 6:2
reassortants having both the HA with a modified cleavage site,
as described above, and the NA of influenza viruses A/VN/1203/
04 (H5N1), A/Hong Kong/213/03 (H5N1), and A/Indonesia/
05/05 (H5N1) respectively, in combination with all other genes
including the complete NS segment of the IVR-116 strain. These
viruses were named VN1203, HK213, and IND05, respectively,
and were used for challenge experiments in addition to the low
pathogenic A/Duck/Singapore-Q/F119/97 (H5N3) (Dk/Sing/
97) virus. For the challenge of ferrets, the IND05 FA (ferret
adapted) virus was generated by infecting ferrets followed by virus
amplification on Vero cells from lung homogenate. No mutations
in HA were revealed.
All of the animal studies were approved by the local authorities:
the chicken study by the Austrian Federal Ministry of Science and
DNS1 H5N1 Influenza Vaccine
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Ethics Committee; one ferret and the macaque studies by the
Institutional Animal Care and Use Committee (IACUC) and the
Committee for Animal Protection of the Ministry of Industry and
Trade of the Czech Republic; and the ferret challenge study by
Retroscreen was conducted in compliance with the UK Home
Office Scientific Animals Procedures Act 1986.
Plasmids and Transfection
cDNAs of H5N1 segments were synthesized (Geneart) based on
the sequences derived from the database: A/VN/1203/04
(Accession numbers AY818135 for HA, AY818141 for NA, and
AY818144 for M), A/Indonesia/05/05 (EF541394 for HA, and
EF541395 for NA), A/Hong Kong/213/03 (AB212054 for HA,
and AB212056 for NA).
All synthesized segments were cloned into the bidirectional
plasmid pHW2006, a synthetically produced analog of pHW2000
[48]. Just as in pHW2000, it contains a Pol I and Pol II expression
cassette for the bidirectional transcription of influenza segments.
Plasmids according to the composition of the desired virus were
combined and the Vero cells were transfected as described by
Kittel et al. [49].
Virus Propagation and Titration
Seed virus stocks were generated by passaging the transfection
supernatant in Vero cells cultivated at 37uC and 5% CO2 in an
Opti-pro medium supplemented with 4 mM L-glutamine and
5 mg/ml porcine trypsin (Sigma). Infectious virus titers in 50%
tissue culture infectious doses (TCID50/ml) were determined in
Vero cells and calculated according to Reed and Muench.
Influenza virus Dk/Sing/97 was propagated in the allantoic
cavity of 9- to 11-day old embryonated hen’s eggs at 37uC.
Allantoic fluid was collected 48 hours (h) post infection (p.i.).
Plaque Assay with and without Trypsin
Vero cells were inoculated with serial tenfold dilutions of
viruses. After 30 minutes (min) of incubation, the inoculum was
removed and the cells were overlaid with 0.6% w/v agar (Sigma)
mixed with 50% v/v Opti-pro medium, 4% v/v saturated
NaHCO3, 6.25% v/v 106 DMEM (Promocell), 1% v/v of 1%
DEAE-Dextran, and with or without 5 mg/ml trypsin (Sigma).
Plaques were counted after 2 to 3 days incubation at 37uC5 %
CO2.
Replication and Induction of Cytokines in Human
Macrophages
Peripheral blood mononuclear cells (PBMCs) were obtained by
gradient centrifugation with Ficcol-Paque (Farmacia). CD14
positive cells were isolated by immunomagnetic sorting by using
the VARIOMACS technique (Miltenyi Biotec GmbH) according
to the manufacturer’s procedure and cultured in polystyrene tissue
culture plates with a hydrophobic surface (Greiner Bio-One).
2610
6 cells per 6-well plate were seeded in an RPMI 1640
medium (Invitrogen) supplemented with 10% FCS (HyClone) and
250 U/ml of recombinant human granulocyte-macrophage colo-
ny stimulating factor (GM CSF; Berlex) and incubated at 37uC
and 5% CO2 for 7 days with the addition of 1 ml medium every
second day.
On day 7, the macrophages were washed and infected with
VN1203DNS1 or VN1203 at a multiplicity of infection (moi) of 2
for the determination of the induction of cytokines or moi of 0.001
for the control of virus replication. After an inoculation time of
30 min, the cells were spun down and resuspended in 1 ml RPMI
1640 medium containing 10% FCS and incubated at 37uC and
5% CO2. Supernatants were harvested at 24 h (p.i.) and the levels
of cytokines (IFN-a, TNF-a, IL-1b, IL-6) were determined by
using the Luminex 100 system (Beadlyte Human Multi-Cytokine
Detection System 2). Moreover, the amounts of IFN-a were
determined by using quantitative cytokine-specific ELISA kits
(PBL Biomedical Laboratories) following the manufacturer’s
instructions. In order to determine the level of virus replication,
cells were cultivated in an RPMI medium supplemented with
trypsin (5 mg/ml) and the supernatants were collected at 6, 24, 48,
and 72 h p.i. and assayed for the presence of infectious virus by a
TCID50 assay on Vero cells.
Induction of Interferon in Human Bronchial Epithelial
Cells (HBE)
HBE cells were infected with influenza VN1203DNS1 or
VN1203 viruses at moi 5. Tissue culture supernatants were
collected at 6 and 24 h p.i. For control 0.5 mg/ml, poly I:C were
transfected to HBE cells by using Lipofectamin 2000 (Invitrogen).
The appropriate serial dilutions of these supernatants and of
human leukocyte IFN (as a standard; Antigenix America Inc.) in
MEM containing L-glutamine and 10% FBS were applied to 96-
well plates with A549 cells, stably transfected with a pGL4.17
plasmid (Promega) comprising the firefly luciferase 2 reporter gene
under the control of the Mx A promoter [50,46]. After incubating
for 16 h at 37uC and 5% CO2, the cells were washed (PBS
containing 2 mM EDTA) and treated with 100 ml/well of lysis
buffer (8 mM MgCl2, 1 mM dithiothreitol, 1 mM EDTA, 15%
glycerol, 25 mM Tris-phosphate buffer pH 7.8). 100 ml/well of
assay buffer (lysis buffer supplemented with 2 mM ATP and
100 mM D-luciferin sodium salt) were added and luciferase activity
was analyzed by using a luminometer (Mediators PHL, Austria)
and a 5
th- parameter logistic standard curve fit (GraphPadPrism
software).
Detection of Serum Antibody Titer by a
Hemagglutination Inhibition Assay (HAI)
Sera were diluted 1:4 with Receptor Destroying Enzyme (RDE;
Denka Seiken, Japan) and incubated at 37uC overnight (o.n.).
Thereafter, the enzyme was inactivated by heat treatment (56uC
for 30 min) and serial two-fold dilutions of sera were prepared in
96-well microtiter plates. 25 ml/well of the standardized antigen (4
hemagglutination units/25 ml) were added. After an incubation
period of 60 min at room temperature (RT), 50 ml of 0.5% cRBC
or 1% hRBC were added and plates were incubated at RT for 60
minutes.
Detection of Neutralizing Antibody Titer by a
Microneutralization Assay (MNA)
Serial twofold dilutions of RDE-pre-treated sera were prepared
in 96-well microtiter plates (Falcon) and 50 ml of a standardized
viral suspension (100 TCID50/50 ml) were added to each well.
After an incubation period of 2 h at 37uC, the Vero cells were
added. The plates were incubated for 20 h, washed and acetone
fixed. An influenza A virus NP-specific monoclonal antibody
(0.125 mg/ml; Chemicon) diluted in a blocking buffer (PBS
containing 1% BSA and 0.1% Tween-20) was added for 1 h.
Following washing, the bound antibodies were detected by
incubating with polyclonal goat anti-mouse IgG HRP conjugate
(0.25 mg/ml; KPL). The plates were washed and the substrate
(TMB, KPL) was added. The reaction was stopped with 1 N
H2SO4. The average absorption at 450 nm (A450) was determined
for the control wells of virus-infected (VC) and uninfected (CC)
DNS1 H5N1 Influenza Vaccine
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a 50% specific signal calculation.
NEP~
average A450 of VC wells ðÞ { average A450 of CC wells ðÞ ½ 
2
z average A450 of CC wells ðÞ
The endpoint titer was expressed as the reciprocal of the highest
dilution of serum with an A450 value less than NEP.
Detection of Vaccine Specific Serum IgG and Mucosal IgA
96-well Nunc Maxisorp plates (transparent for serum IgG ELISA
and white for mucosal IgA ELISA) were coated with 0.5 mg/ml
(100 ml/well) of the recombinant hemagglutinin of the A/VN/
1203/04 (H5N1) influenza virus (ferret IgA measurement) (Sino-
biological Ltd.) or purified VN1203DNS1 virus (mouse IgG
measurement) at 4uC o.n. The plates were washed (PBS containing
0.1% Tween-20) and blocked with assay buffer [PBS containing
0.5% I-Block (Tropix) and 0.1% Tween-20]. Serially twofold
diluted samples (serum for IgG ELISA or nasal wash for mucosal
IgA ELISA) were added and incubated at RT for 1.5 h. On each
plate, the reference standards for the respective target antibody,
appropriately diluted in the assay buffer, were included. The
standard curve for the assessment of H5-specific IgG/IgA was
established by utilizing a pool of serum samples (IgG reference
standard) or nasal washsamples (IgA reference standard), exhibiting
a detectable signal that was determined in a preliminary endpoint
ELISA. A 1:8 dilution of the IgA reference standard was defined as
100 arbitrary units (AU) of H5-specific IgA per ml. After washing,
H5-specific IgG or IgA antibodies were detected with goat anti-
mouse IgG conjugated to HRP (0.25 mg/ml; Rockland Immuno-
chemicals) or goat anti-ferret IgA conjugated with AP (0.25 mg/ml;
Rockland Immunochemicals). The plates were incubated for 1 h,
washed again, and TMB (KPL) substrate was added for serum IgG
ELISA or Lumi-Phos Plus substrate for mucosal IgA ELISA
(Aureon Biosystems). The reaction of the IgG ELISA was stopped
with 2 M H2SO4 and the optical density was determined by using a
Biotek photometer (measurement wavelength 450 nm; reference
wavelength 630 nm). The luminescence signal in the mucosal IgA
ELISA was measured after incubating the plates for 60 min in the
dark with a luminometer(Mediators PHL, Austria). H5-specificIgG
were presented in log2 titer while the concentration of IgA in the
individual samples was expressed in AU/ml based on the IgA
reference standard calibration curve by the 4-parameter non-linear
logistic curve fit (GraphPadPrism software).
In the mucosal samples H5-specific IgA antibodies were
normalized. A standard quantitative ELISA was performed by
using affinity purified goat anti-ferret IgA (a -chain; 0.25 mg/ml;
Novus Biologicals), nasal wash samples, goat anti-ferret IgA (a-
chain; 0.25 mg/ml; Rockland Immunochemicals) conjugated with
HRP, and TMB substrate (KPL). The IgA concentration in each
sample was calculated based on the IgA reference standard curve
by a 4-parameter non-linear logistic fit. A dilution of 1:20 of the
IgA reference standard was defined as 100 AU of the total IgA/ml.
The final normalized results were expressed in H5-specific AU/
100 AU of the total IgA for each individual nasal wash sample.
Pathogenicity and Infectivity Study in Chickens
The VN1203DNS1 vaccine strain virus was administered
intravenously (i.v.) to a group of eight 5–6 week old White
Leghorn SPF chickens at a dose of 7.1 log10 TCID50/animal in
0.2 ml. In parallel, two other groups of chickens were treated
intranasally (i.n.) with 0.1 ml of the same virus preparation (6.8
log10 TCID50/animal) or with PBS. The animals were observed
daily for clinical signs and death over a period of 14 days. On day
3, post administration oropharyngeal and cloacal swabs were
collected from each chicken and virus replication was assayed by a
TCID50 assay on Vero cells.
Protection Efficacy Study in Mice
Groups of 6–8 week old outbred female mice were immunized
i.n. under narcosis once or twice with 50 ml of the VN1203DNS1
virus at a dose of 5.3 log10 TCID50/animal, 3 weeks apart. The
control group was treated with PBS. Three weeks post each
immunization, 6 animals from each group were bled and sera were
analyzed by HAI and ELISA. The remaining animals treated with
the vaccine strain or PBS were challenged under narcosis (6 mice
per virus) with 50 ml of VN1203 (3.3 log10 TCID50/animal),
HK213 (3.2 log10 TCID50/animal), IND05 (2.2 log10 TCID50/
animal), or Dk/Sing/97 (4.2 log10 TCID50/animal) viruses. On
day 3 and 5 post challenge, 6 mice from each group were
euthanized; the lung and nasal tissues were collected and a 10%
w/v tissue homogenate was prepared. The viral load was
determined by a TCID50 assay on Vero cells for VN1203,
HK213, and IND05 or on MDCK cells for Dk/Sing/97.
Pathogenicity and Immunogenicity in Ferrets
A group of 22 ferrets (11 males and 11 females) (Biotest, Czech)
received two intranasal doses each 7.8 log10 TCID50/animal of the
VN1203DNS1 virus in a volumeof 0.5 ml via a spray device, 4 weeks
apart. The virus was purified and formulated in SPGN buffer (6% w/
vs u c r o s e ,3 . 8 m MK H 2PO4, 7.2 mM K2HPO4,4 . 9 m ML -
glutamate, and 75 mM NaCl). At the same time, the control group
(n=16) was immunized i.n. with the same amount of SPGN. The
animals were examined on a daily basis up to 3 weeks post the second
immunization. Sera were collected before the first and second
immunization as well as 3 weeks after the second immunization. Four
days p.i., 10 animals of the immunized and 6 animals of the mock
treated group were sacrificed, tissues were collected (lung, nasal
mucosa, brain, kidney, and intestinal tissue) and 10% w/v tissue
homogenates were investigated for the viral load by titration on Vero
cells. Sera were processed by HAI and MNA.
Protection Efficacy in Ferrets
This experiment was performed by Retroscreen Virology Ltd.,
UK. Seven month old seronegative male ferrets were housed in
three groups under conventional conditions in floor pens.
Anesthetized ferrets (light anesthesia was induced via the
inhalation of isoflurane) were immunized intranasally either once
(7 animals) or twice (8 animals, with an interval of 18 days) with
8.1 log10 TCID50/animal of the VN1203DNS1 virus (tissue
culture supernatant) or with PBS (6 animals). 14 days after the final
immunization, the anesthetized animals were challenged intrana-
sally with 6.3 log10 TCID50/animal of the reassortant virus IND05
FA. The body weight and clinical symptoms e.g. nasal discharge,
sneezing, dyspnea, the level of activity as well as mean maximum
and mean sum of the inflammatory cell counts in nasal washes
were assessed from the 1
st to 7
th day.
Collection of Blood and Nasal Washings from Ferrets
1 ml PBS was instilled into each nostril of the anesthetized
animal by using a displacement pipette. The ferret was then
turned over with its nose resting just over the collection container
(Petri-dish). The nostrils were gently tickled by using a pipette tip
DNS1 H5N1 Influenza Vaccine
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wash, which were collected into a Petri-dish and supplemented
with 1 ml of media. Nasal washes were collected before
immunization, 14 days p.i. and 1, 3, 5, and 7 days post challenge.
The nasal wash fluids were frozen at 280uC.
Blood was collected by piercing the shaved and disinfected
upper tail area with a syringe needle. Blood was processed to
serum and stored at 220uC.
Evaluation of the Pathogenicity and Immunogenicity in
Macaques
The VN1203DNS1 virus was administered i.n. (7.8 log10
TCID50/animal) once as a spray in Rhesus macaques (Macaca
mulatta) ranging in age from 2 to 3 years (Biotest Ltd., Czech
Republic). The animals were monitored for clinical signs by daily
observations and weekly body weight measurements. In addition,
standard hematological and plasma biochemical analyses were
performed. Blood samples were collected before immunization
and 4 weeks p.i. Nasal washing samples were collected before and
2 days p.i. in order to evaluate the vaccine virus shedding by
TCID50 titration on Vero cells and to determine the level of
cytokines.
Detection of Cytokines in Macaque Nasal Washings
The level of cytokines in the nasal washings was measured with
the Luminex 100 system (Upstate, Temecula, CA).
Results
Generation of H5N1 Reassortants
The vaccine candidate VN1203DNS1 was designed as a 5:3
reassortant, inheriting the HA, NA, and M genes from the H5N1
isolate A/VN/1203/04 and the remaining genes from the IVR-
116 vaccine strain (see Materials and Methods). The NS fragment
was modified by the complete deletion of the NS1 ORF. This virus
was rescued entirely from cDNA clones by the co-transfection of a
set of eight plasmids into Vero cells. Plasmids encoding genes of
avian origin were constructed based on the sequence data
obtained from the GeneBank. The polybasic cleavage site of HA
was replaced by the sequence TETR/GLF, which was found to be
genetically more stable in birds than the sequence (RETR/GLF)
that is typical for avirulent H5 viruses and that is widely used for
H5N1 vaccine development [47].
The resulting vaccine candidate possessed several attenuating
factors, including the modification of HA and NS genes in
combination with the replacement of the majority of the avian
genes by that of the IVR-116 virus.
By a similar approach, several 6:2 reassortants, namely
VN1203, HK213, and IND05 with functional NS1 gene and
modified HA, were generated. These viruses were intended to be
replication competent in vivo and suitable for challenge experi-
ments in animals.
For the HAI and the MNAs, 6:2 reassortants VN1203 and
IND05 were constructed comprising an additional mutation
(S223N) in the HA, as described by Hoffman et al. [51]. The
introduced mutation improved HAI performance of the VN1203
virus with chicken red blood cells (cRBC) reached the level of
sensitivity attained with horse red blood cells (hRBC), but did not
have any effect on the IND05 virus. Therefore, the assay with the
IND05 virus was additionally performed with hRBC.
VN1203DNS1 Virus Grows to High Titers in Vero Cells
Rescued virus VN1203DNS1 was able to grow in Vero cells to a
titer of 8.5 log10 TCID50/ml. No mutations were detected in the
avian HA, NA, or M genes after 8 passages in the Vero cells. The
antigenic properties of the VN1203DNS1 virus were indistin-
guishable from the reference strains (performed by Medical
Research Council, London, UK; data not shown).
In order to monitor the HA modification, virus replication in
the presence and absence of trypsin was investigated in Vero cells
by a plaque assay. No plaques were noticed in the absence of
trypsin for the VN1203DNS1 virus in contrast to the clear plaques
observed in cells cultivated with trypsin (data not shown).
VN1203DNS1 Virus Triggers Innate Immune Response in
HBE Cells and Human Macrophages
Influenza viruses encoding functional NS1 protein are able to
antagonize the cytokine response of infected cells, whereas DNS1
mutant viruses induce an elevated level of type I IFNs and other
pro-inflammatory cytokines [45,46]. We used human bronchial
epithelial cells (HBE) and macrophages in order to evaluate the
innate immune response that is triggered by a VN1203DNS1 virus
infection. The type I/III IFN response in HBE cells was studied by
utilizing the MxA-driven luciferase reporter bioassay (Fig. 1). At
time points 6 and 24 h p.i., the vaccine candidate induced
significantly (p,0.03) higher increases of luciferase signals
compared to a virus containing the full size NS1 gene. The signal
induced by the transfected poly I:C was used as a control. The
level of pro-inflammatory cytokines (IFN-a, TNF-a, IL-6, and IL-
1b) induced by the VN1203DNS1 virus in macrophages was up to
tenfold higher when compared to the virus with a full size NS1
gene (Fig. 2B). The DNS1 virus could not replicate in
macrophages in contrast to the analogous virus containing the
unaltered NS1 gene, which replicated to max titers of approx. 6
log10 TCID50/ml (Fig. 2A). These results confirmed the
replication deficient phenotype of the VN1203DNS1 virus in the
IFN competent cells associated with the enhanced triggering of the
innate immune system.
Pathogenicity of VN1203DNS1 Virus in Chickens
In order to estimate the level of the attenuation of the
VN1203DNS1 vaccine candidate in chickens, five to six week
old white leghorn SPF chickens (eight per group) were inoculated
Figure 1. Induction of IFN in human bronchial epithelial (HBE)
cells. HBE cells were infected with VN1203DNS1 or VN1203 at moi 5. At
6 and 24 h p.i. supernatants were collected. The level of secreted IFN
was determined by a bioassay based on the A549 cell line that was
stably transfected with a luciferase reporter gene under the control of
the MxA promoter. As a control, HBE cells were transfected with 0.5 mg/
ml poly I:C, and supernatants were treated like these of the infected
cells. Relative light units (RLU) represent the measured luciferase
activity. The data from the most representative experiment are shown. *
indicates p,0.03, ** p,0.02 determined by a Student’s t-test.
doi:10.1371/journal.pone.0005984.g001
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respectively. No signs of illness or pathological lesions were
detected in any of the infected birds. The analysis of the chicken
cloacal or oropharyngeal samples taken three days post i.v. or i.n.
infection revealed no infectious virus in the samples, in turn
verifying the replication-deficient phenotype of this virus (results
not shown).
VN1203DNS1 Virus Provides Cross-reactive Protection in
Mice
To determine whether the i.n. immunization of mice with the
VN1203DNS1 virus provides protection against homologous or
heterologous challenge, the animals were immunized i.n. once or
twice with 5.3 log10 TCID50/animal of VN1203DNS1 virus. Two
days p.i., four animals were sacrificed for the determination of the
infectious viral progeny in mouse organs. No viral growth was
detected in the nasal, lung, brain, or spleen tissues (data not
shown). Sera taken three weeks p.i. were analyzed by HAI and
ELISA. HAI titers (made with cRBC) were low (data not shown).
However, substantial serum IgG response was found by ELISA
after the first immunization (GMT=2940) and significantly
increased after boosting immunization (GMT=17828) (Fig. 3).
Three weeks after the first or second immunization, the mice
were challenged with replicating viral reassortants belonging to
H5N1 clade 1 (VN1203, HK213) or clade 2.2 (IND05) as well as
with virus Dk/Sing/97 (H5N3). All the viruses were able to grow
in the lungs of naı ¨ve mice in the range of 4.0–5.0 log10 TCID50/ml
(Table 1). Single intranasal immunization provided substantial
Figure 2. Viral replication and induction of cytokines in human macrophages. (A) Human macrophages were infected with VN1203DNS1 or
VN1203 at a moi of 0.001. The level of viral replication was determined at different time points by a TCID50 assay on Vero cells. (B) Seven day old
macrophages were infected with VN1203DNS1 or VN1203 at a moi of 2. The supernatants of the infected cells were harvested 24 h p.i and assayed
for IFN-a, TNF-a, IL-1b, and IL-6. The experiment was repeated three times. The data of one representative experiment are presented as a mean of two
measurements. The mock value is subtracted.
doi:10.1371/journal.pone.0005984.g002
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virus clearance from the lungs. Statistically significant titer
reduction of the challenge viruses was detected on day 3 after
infection compared to the control group (p,0.05). On day 5, the
levels of the viral load in the lungs of the majority of animals were
undetectable, irrespective of the challenge virus. After two
immunizations, the virus VN1203DNS1 provided nearly full
protection from the infection with the challenge viruses belonging
to different clades.
Attenuation, Immunogenicity, and Protective Efficacy in
Ferrets
To obtain more detailed information about the safety and
immunogenic potential of the VN1203DNS1 virus, a repeated
dose toxicity study was conducted in ferrets. The animals were
administered two i.n. doses (7.8 log10 TCID50/animal) of the
VN1203DNS1 virus, four weeks apart. In life monitoring
performed during seven weeks after the first inoculation indicated
no major differences in clinical signs, body weight, or temperature
between the treated and control groups (data not shown). No
vaccine virus shedding was observed in the nasal washes taken on
day three (data not shown). The examination of the viral load in
organs taken on day three, post first immunization, revealed no
infectious virus in the lung, brain, (three sections including the
cerebrum, cerebellum, and pons), intestine, or kidney tissues.
Infectious virus was isolated in 2 of the 10 animals (at traceable
quantities) only from homogenized nasal turbinates, which most
likely represent the residual particles from the high viral
inoculation load. The serum antibody response was determined
after the 1
st and 2
nd immunizations by HAI and MNA (Fig. 4). A
single vaccination induced an increase in antibody titers in the
HAI test (GMT=36, cRBC) against the homologous VN1203
antigen. The second vaccination doubled the titers (GMT=84).
HAI (hRBC) antibody response to the heterologous IND05
antigen was detected only in one-half of the animals. An MNA
test revealed a statistically significant increase in antibody titers
after single immunization against homologous (GMT=545) and
heterologous (GMT=93) viruses followed by a further increase
after the second immunization, GMT=1351 and GMT=181,
respectively.
In a separate experiment, protective immunity against a
heterologous strain was tested in animals that were immunized
i.n. with 8.1 log10 TCID50/animal of VN1203DNS1 once or twice
Figure 3. Determination of virus-specific mouse serum IgG
titers. Mice were immunized once or twice with 5.3 log10 TCID50/
animal of the VN1204DNS1 virus. The control mice were treated with
PBS. Serum was collected three weeks p.i. and the level of IgG was
determined by ELISA. The serum titers of the individual mice (symbols)
expressed as log2 and the GMTs (horizontal line) for each group of mice
are shown. * indicates p,0.0001 determined by a Student’s t-test.
doi:10.1371/journal.pone.0005984.g003
Table 1. Replication of challenge viruses in mice immunized with the VN1203DNS1 virus.
Treatment Group Challenge Virus 3 d post challenge 5 d post challenge
No. of Animals
Protected/Total No.
a
Mean Virus
Titer log10
b
No. of Animals
Protected/ Total No.
a
Mean Virus
Titer log10
b
1 Dose VN1203 2/6 2.660.5 6/6 ,1.5
HK213 3/6 3.060.6 5/6 1.660.4
IND05 1/6 2.960.3 5/6 1.660.4
Dk/Sing/97 2/6 2.060.4 6/6 ,1.5
2 Doses VN1203 6/6 ,1.5 6/6 ,1.5
HK213 6/6 ,1.5 6/6 ,1.5
IND5 6/6 ,1.5 6/6 ,1.5
Dk/Sing/97 6/6 ,1.5 6/6 ,1.5
PBS VN1203 0/6 4.960.2 0/6 4.460.2
HK213 0/6 5.260.2 0/6 4.560.3
IND05 0/6 4.060.1 0/6 3.760.3
Dk/Sing/97 0/6 4.160.3 0/6 4.560.3
aMice with lung virus load ,1.5 log10 TCID50/ml were classified as being protected.
bThe virus titers are expressed as the mean log10 TCID50/ml6standard error (S.E.) from 6 animals. The limit of virus detection was 1.5 log10 TCID50/ml. Tissues where no
virus was detected were defined as 1.5 log10 TCID50/ml for the calculation of the mean titer.
Mice (6 animals per group) were administered i.n. one or two doses of the VN1203DNS1 virus (5.3 log10 TCID50/animal) three weeks apart and were challenged with
homologous VN1203 (3.3 log10 TCID50/animal), or heterologous HK213 (3.2 log10 TCID50/animal), IND05 (2.2 log10 TCID50/animal) and Dk/Sing/97 (4.2 log10 TCID50/
animal) viruses three weeks post each immunization. The decrease of the mean virus titers measured in the vaccinated group compared to the PBS treated group was
significant in all the groups as determined by the Mann-Whitney U-test (p,0.05).
doi:10.1371/journal.pone.0005984.t001
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HAI or MNA titers to the heterologous IND05 strain were
detected only after double immunization (results not shown).
Ferrets were challenged with the IND05 FA virus taken in a dose
of 6.3 log10 TCID50/animal. Although the challenge virus did not
elicit significant symptom scores, its replication in the respiratory
tract of ferrets reached a peak of 3.3 log10 TCID50/ml on day
three, post challenge, in the PBS control group (Fig. 5). In the
vaccine groups, single and double immunization equally brought
the challenge virus to undetectable levels in the nasal washings at
any time point after the challenge. This protection at least partially
could be attributed to a local IgA immune response. As shown in
Fig. 6, H5 specific IgA antibodies in the nasal washes were
detected in two of the seven animals after a single immunization,
although all of the vaccinated animals responded after the second
dose of the vaccine.
Attenuation and Immunogenicity of the VN1203DNS1
Virus in Rhesus Macaques
Since nonhuman primates were shown to be a suitable model
for the evaluation of H5N1 influenza pathogenesis [52], next we
checked the performance of the VN1203DNS1 virus in Rhesus
macaques focusing on attenuation and immunogenicity. Adult
macaques (2.5–4 years old) were immunized i.n. with 7.8 log10
TCID50/animal of virus without narcosis in order to limit virus
application only to the upper part of the respiratory tract
mimicking immunization in humans. Vaccination did not provoke
any clinical manifestation in the macaques such as fever or
respiratory symptoms, confirming the safety of the vaccine in the
primate model.
The replication deficient phenotype of the VN1203DNS1 virus
was corroborated by the absence of virus isolation from the nasal
washings taken on day 2 and 4, p.i. (data not shown).
Figure 4. Serum HAI and neutralizing (MNA) antibody titers after single or double i.n. immunization of ferrets. Ferrets received two i.n.
doses of 7.8 log10 TCID50/animal of VN1203DNS1 virus, four weeks apart. Sera were collected 29 days after the 1
st and then 21 days after the 2
nd
immunization and were analyzed for homologous (VN1203) and heterologous (IND05) HAI antibodies (A, B) with cRBC and hRBC or neutralizing
(MNA; C, D) antibodies. The titers of the individual ferrets (symbols) and the mean titers (horizontal line) are shown. * indicates p,0.0001, and **
p,0.05 determined by a Student’s t-test. An undetectable HAI antibody titer was assigned a value of ,8. An undetectable neutralizing antibody titer
was assigned a value of ,16.
doi:10.1371/journal.pone.0005984.g004
Figure 5. Replication of heterologous challenge virus in
immunized ferrets. Ferrets that received either PBS or one or two
doses of 8.1 log10 TCID50/animal of the VN1203DNS1 virus were
challenged with 6.3 log10 TCID50/animal of IND05 FA virus two weeks
post the last immunization. Nasal samples were collected at the
indicated time points and level of infectious virus was determined by
the titration on Vero cells. The lower limit of detection is 2 log10 TCID50/
ml indicated by the horizontal dashed line.
doi:10.1371/journal.pone.0005984.g005
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of IL-1b, IL-2, IL-6, IL-8, IL-4, IL-12p70, IFNc, TNFa, and GM
CSF cytokines were detected in vaccinated, but not control,
macaque nasal lavage fluids collected 2 days post immunization,
although statistically significant increase was shown only for IL-1b,
IFNc, TNFa, and GM CSF cytokines (Fig. S1). The spectrum of
induced cytokines indicated the possible involvement of epithelial
as well as immune competent cells in the generation of antiviral
innate immune response similar to the wild type influenza virus
infection in humans [53].
A single immunization with the VN1203DNS1 virus induced a
significant increase in HAI (cRBC) (GMT=64) and neutralizing
antibodies (GMT=362) against homologous virus VN1203.
Moreover, these antibodies persisted during a 6-month observa-
tion period and titers dropped only 2 times (data not shown). An
increase against the heterologous IND05 virus was detected by
HAI assay only with hRBC (GMT=45) but not in MNA
(GMT=16) (Fig. 7). Therefore, intranasal immunization of non-
human primates with the strain VN1203DNS1 was safe, did not
provoke virus shedding, and induced a specific antibody response.
Discussion
The increased incidence of human infection with highly
pathogenic H5N1 avian influenza viruses with high mortality rate
serves as an alarm for the global society. The problem does not
only concern the efficacy of the licensed types of influenza
vaccines, but also the capacity of the world industry to produce
sufficient doses of any influenza vaccine for stock piling. A
pandemic vaccine must be capable of inducing protection against
hypothetical viruses that so far have not spread in the human
population, but that may arise. This difficult situation evokes
several new directions in influenza vaccine research and
development. Limitations in the availability of embryonated
chicken eggs stimulate efforts to use continuous cell lines for
influenza vaccine production [54,55]. The necessity for antigen
sparing and the problem of cross-reactivity has sparked an
intensive search for new immunological adjuvants [10,56]. Live
attenuated intranasal and VLP vaccines that are capable of
inducing secretory IgA and T-cell immunity are considered as a
possible solution for obtaining broader protection against subtype
specific antigenic variants. Mucosal vaccines might be especially
useful during pandemic periods due to the simplicity of their
application.
We developed a new type of intranasal influenza vaccine that
aims at combining the strong sides of live and inactivated influenza
Figure 6. Detection of vaccine virus-specific IgA in the nasal
wash samples of immunized ferrets. Ferrets were immunized
either with PBS once (6 animals) or with the vaccine virus VN1203DNS1
once (7 animals) or twice (8 animals) with a dose of 8.1 TCID50/animal.
Nasal wash samples were collected prior to immunization (pre) and two
weeks after each immunization. Individual vaccine virus specific IgA
levels were normalized based on the total IgA content of each sample
and expressed as vaccine virus-specific IgA RLU/100 AU (arbitrary units)
of total IgA. The means (horizontal lines) and standard errors of mean
(vertical lines) are presented. Animals with a 2.5-fold increase in IgA titer
following immunization were considered as responders.
aNo. of
responders/total no. of immunized animals.
doi:10.1371/journal.pone.0005984.g006
Figure 7. Serum antibody responses after the single i.n.
immunization of adult Rhesus macaques. A group of four macaques
was immunized i.n. with VN1203DNS1 at a dose of 7.8 log10 TCID50/
animal. Sera were collected four weeks p.i. and HAI with homologous
VN1203 (cRBC) or heterologous IND05 (cRBC and hRBC indicated by
a)
antigens and MNA titers were performed. Undetectable HAI antibody
titer was assigned a value of ,8. An undetectable neutralizing antibody
titer was assigned a value of ,16. * indicates p,0.05 determined by the
Mann-Whitney U-test.
doi:10.1371/journal.pone.0005984.g007
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attenuated, replication deficient vaccine viruses with deleted NS1
ORF and, therefore, lacking antagonistic effects on the innate
immune system. Innate immunity is the first line of defense against
viruses and microbes and acts nearly immediately to limit the early
proliferation and spread of infectious agents. This includes the
activation of phagocytic and antigen-presenting cells, such as
dendritic cells (DCs) and macrophages, as well as the initiation of
inflammatory responses through the release of a variety of
cytokines, chemokines, and antimicrobial factors, such as IFNs
and defensins [57,58]. The NS1 protein is the main factor that
enables influenza viruses to invade the host and successfully
replicate on the background of the down regulated IFN system
[59,60]. This function of the NS1 protein is required at the first
hours after infection, and determines the early and abundant
mode of its synthesis [59]. The impairment of NS1 protein
function leads to abortive replication due to the induction and
activation of a variety of antiviral proteins such as protein kinase R
(PKR) and 29,59-oligoadenilate synthetase (OAS) molecules,
leading to an antiviral state in infected and neighboring cells
[61] [43,46]. Therefore, immunization with the DNS1 vaccine
could be considered similar to vaccination with virus-like particles,
since it does not induce vaccine virus shedding [30]. At the same
time, DNS1 mutant viruses are infectious for nasal respiratory cells
and can evoke synthesis and the presentation of viral antigens
similar to live attenuated vaccines [46].
Important, that the method of attenuation of viruses by deleting
interferon antagonist must be suitable for different age groups of
people and people having innate immune deficiencies. It should be
noted that innate immune system is already active in newborn
children [62]. The autosomal recessive form of human complete
Stat-1 deficiency is an extremely rare disorder, so far reported in
three unrelated patients [63]. Such children usually develop
disseminated bacillus Calmette-Gue’rin (BCG) after vaccination
and subsequently died of viral illnesses. Another cellular defense
mechanism against influenza mediated by dsRNA activated
protein kinase (PKR) was also shown to be matured during foetal
development (reviewed by Garcia et al. [64]. To our knowledge
PKR deficiency related pathology was not described in people. In
general, innate immune deficiency should be suspected in children
with severe mycobacterial or viral diseases [63]. Such children
should be excluded from any vaccination programs. In elderly,
immunosenescence renders vaccination to be less effective. Aging
leads to a decline in the response to infection by both the innate
and adaptive immune systems. Therefore, DNS1 vaccine ap-
proach has to be evaluated more carefully in old people and
patients with secondary immune deficiencies.
We applied the DNS1 technology to construct H5N1 vaccine
candidates. Such a vaccine might be an appropriate alternative to
conventional vaccines in case of a pandemic, due to simplicity of
mucosal immunization. In addition, in contrast to live influenza
vaccines, the absence of replication and shedding may decrease
the risk of adverse events and vaccine virus spread in immuno-
logically naı ¨ve population, particularly children.
The vaccine virus was created as a 5:3 reassortant containing a
combination of three avian virus genes (HA with a modified
cleavage site, NA and M) with the other 5 genes from the IVR-116
vaccine virus strain, which was adapted for growth in Vero cells
and modified by the deletion of NS1 ORF. The inclusion of the
avian M gene and, therefore, the encoding of the M1 and M2
proteins of emerging H5N1 pandemic strains may bring important
protective epitopes for a T- and B- cell immune response, which
might not be present in old influenza human isolates. At the same
time, the 5:3 genome composition of the vaccine reassortant
should not affect the safety level of the vaccine since modified NS
and HA genes are present as main contributors of attenuation.
We demonstrated that H5N1 DNS1 deletion mutant viruses can
be successfully produced in IFN deficient Vero cells, which are
qualified for human use, reaching titers exceeding 8.0 log10/ml, in
turn making the production of such vaccines feasible and
comparable to production in eggs. We evaluated the DNS1
H5N1 vaccine candidate in three animal models, namely mouse,
ferret, and non-human primate. None of the animals developed
any serious adverse events or lung pathology, thus reinforcing the
safety profile of the vaccine virus. No infectious virus was isolated
from distant studied organs or the nasal washings of inoculated
animals, confirming the replication deficient phenotype of the
vaccine candidate. Two cases of virus isolation from destructed
nasal tissue samples could be explained by vaccine virus survival
after the application of the high viral dose (7.5 log10/ferret) in
stabilizing formulation.
We confirmed for the H5N1 vaccine candidate the previous
observations that DNS1 mutant viruses intensively trigger the
innate immune response of infected cells. We demonstrated that
the infection of human bronchial epithelial cells and macrophages
caused the profound release of type I IFNs and other pro-
inflammatory cytokines analogous to DNS1 mutants of other
subtypes [45]. Intranasal immunization of macaques showed
increased levels of the pro-inflammatory cytokines and chemokines
in the nasal mucosa. The spectrum of detected cytokines indicates
that both infected epithelial cells as well as immune competent
cells are most probably involved in cytokine production. It was
reported that type I IFNs as well as IL-1b, IL-12, IL-18, and GM-
CSF can exhibit mucosal adjuvant activity for the induction of
serum IgG and mucosal IgA antibody responses when nasally
administered with protein antigens [65]. Therefore, we hypoth-
esize that DNS1 vaccines can stimulate an adaptive immune
response without adding immunological adjuvants (self adjuvant
effect).
Studies in animals demonstrated that despite a replication
deficient phenotype, the H5N1 DNS1 vaccine virus was
immunogenic in mice, ferrets, and monkeys. Significant serum
antibody response to a homologous strain was detected by
different methods in all animals. However, in mice the IgG titers
were detected after the first immunization only in ELISA but not
by the functional HAI assay with cRBC. Therefore, we tested the
protection efficacy in mice by using four different H5N1 and
H5N3 challenge viruses of various clades that are capable of
replicating in mouse lungs efficiently. Surprisingly, the rate of
protection was nearly equal against all the challenge viruses
irrespective of their antigenic properties. One immunization was
sufficient for the accelerated clearance of the infection from mouse
lungs, whereas complete protection was achieved after two
immunizations. The lack of HAI antibodies in mice remains to
be explained since in other animal models, the functional assays
revealed a substantial antibody response. In ferrets and macaques,
the first immunization was sufficient to detect HAI antibody titers
to VN1203 antigen. Moreover, in macaques, a comparable
antibody response to both viral clades was obtained after a single
immunization when hRBC were used. A challenge experiment in
ferrets revealed that a single immunization was effective for
preventing an infection with a heterologous strain despite the lack
of HAI antibodies in some animals. Thus, the appearance of
neutralizing antibodies to IND05 detected in MNA in turn
correlated better with the protection of ferrets than HAI
antibodies. Besides for systemic cross-neutralizing antibodies, the
induction of H5 specific mucosal IgA that was detected in some
ferrets after the first immunization as well as the T-cell response
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virus. Unfortunately, the method for measurement for the T-cell
response in ferrets is not yet established.
Our results demonstrate the potency of the H5N1 DNS1
vaccine candidate for evoking a cross-reactive H5N1 specific
immune response in three animal models. However, the protection
efficacy of this vaccine candidate remains to be confirmed with
non-modified highly pathogenic H5N1 viruses. An experiment in
macaques is currently in progress.
The DNS1 vaccine approach is applicable for any of the
influenza subtypes. The safety and immunogenicity of the
influenza A H1N1 vaccine strain lacking the NS1 gene was
studied in a first-in-man clinical trial, showing the full safety profile
and a high immune response in adult volunteers (paper in
preparation). The Phase I clinical evaluation of the intranasal
H5N1 pandemic DNS1 vaccine candidate is ongoing.
Supporting Information
Figure S1 Level of cytokines in nasal washings of macaques. A
group of four macaques was immunized i.n. with VN1203DNS1 at
a dose of 7.8 log10 TCID50/animal. Nasal washings were
collected 2 days p.i. Cytokines were measured by using the
Luminex 100 system (Beadlyte Human Multi-Cytokine Detection
System 2)
Found at: doi:10.1371/journal.pone.0005984.s001 (0.28 MB TIF)
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